European collaborative study of early-onset bipolar disorder: Evidence for genetic heterogeneity on 2q14 according to age at onset

Flavie Mathieu 1  2,*, Marie-Hélène Dizier 3  4  5, Bruno Etain 1  2  6, Stéphane Jamain 1  2, Marcella Rietschel 7, Wolfgang Maier 8, Margot Albus 9, Patrick McKeon 10, Siobhan Roche 11, Douglas Blackwood 12, Walter J. Muir 12, Chantal Henry 1  2  6, Alain Malafosse 13, Martin Preisig 14, François Ferrero 15, Sven Cichon 16, Johannes Schumacher 17, Stephanie Ohlraun 8, Peter Propping 17, Rami Abou Jamra 17, Thomas G. Schulze 7  18, Diana Zelenica 19, Céline Charon 19, Andrej Marusic 20, Mojca C. Dernovsek 20, Hugh Gurling 21, Markus Nöthen 17, Mark Lathrop 19, Marion Leboyer 1  2  6, Frank Bellivier 1  2  6.

1 Institut Mondor de Recherche Biomédicale INSERM : U955, Université Paris XII Val de Marne, IFR10, FR
2 Fondation FondaMental Hôpital Albert Chenevier, Pôle de Psychiatrie 40, Rue de Mesly 94010 Créteil CEDEX, FR
3 Variabilité Génétique et Maladies Humaines Université Paris-Diderot - Paris VII, INSERM : U946, Igm fondation Jean Dausset ceph 27 rue Juliette Dodu 4ème etage 75010 paris, FR
4 Institut Universitaire d'Hématologie Université Paris-Diderot - Paris VII, Paris, FR
5 CEPH, Centre d'Etude du Polymorphisme Humain Fondation Jean Dausset, Paris, FR
6 Service de psychiatrie Assistance publique - Hôpitaux de Paris (AP-HP), Hôpital Henri Mondor, Hôpital Albert Chenevier, Créteil, FR
7 Division Genetic Epidemiology in Psychiatry Central Institute of Mental Health, Mannheim, DE
8 Department of Psychiatry University of Bonn, Bonn, DE
9 Department of Psychiatry and Psychotherapy District Hospital Haar, Vockestr. 72, 85540 Haar, DE
10 Department of Psychiatry St. Patrick's Hospital, Dublin, IE
11 Smurfit Institute of Genetics Trinity College, Dublin, IE
12 Division of Psychiatry University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, GB
13 Department of Neuropsychiatry Belle-Idée Hospital, Geneva, CH
14 Department of psychiatry University Hospital - Lausanne, Lausanne, CH
15 Department of psychiatry University Hospital - Geneva, Geneva, CH
16 Life & Brain Center - Department of Genomics University of Bonn, Institute of Human Genetics, Bonn, DE
17 Institute of Human Genetics University of Bonn, Bonn, DE
18 Department of Psychiatry and Psychotherapy Georg-August-Universität Göttingen, Göttingen, DE
19 CNG, Centre National de Génotypage CEA : DSV/IG, 2 rue Gaston Crémieux CP5721 91057 EVRY Cedex, FR
20 Institut de Public Health of the Republic of Slovenia Institute of Public Health, Ljubljana, SI
21 Department of psychiatry and behavioural Sciences Windeyer Institute for Medical Sciences, Royal Free and University College London Medical School, Molecular psychiatry laboratory, London, GB

* Correspondence should be adressed to: Flavie Mathieu <flavie.mathieu@inserm.fr>
# Mathieu F and Dizier MH contributed to this work equally.

Abstract
Bipolar disorder has a genetic component, but the mode of inheritance remains unclear. A previous genome scan conducted in 70 European families led to detect 8 regions linked to bipolar disease. Here, we present an investigation of whether the phenotypic heterogeneity of the disorder corresponds to genetic heterogeneity in these regions using additional markers and an extended sample of families. The MLS statistic was used for linkage analyses. The Predivided Sample Test and the Maximum Likelihood Binomial methods were used to test genetic homogeneity between early onset bipolar type I (cut-off of 22 years) and other types of the disorder (later onset of bipolar type I and early onset bipolar type II), using a total of 138 independent bipolar-affected sib-pairs. Analysis of the extended sample of families supports linkage in four regions (2q14, 3p14, 16p23 and 20p12) of the eight regions of linkage suggested by our previous genome scan. Heterogeneity testing revealed genetic heterogeneity between early and late onset bipolar type I in the 2q14 region (p=0.0001). Only the early form of the bipolar disorder but not the late form appeared to be linked to this region. This region may therefore include a genetic factor either specifically involved in the early onset bipolar type I or only influencing the age at onset. Our findings illustrate that stratification according to age at onset may be valuable for the identification of genetic vulnerability polymorphisms.

Author Keywords Bipolar disorder; genetic heterogeneity; age at onset
INTRODUCTION

Although bipolar disorder (BP) has a genetic component, its mode of inheritance remains obscure and no vulnerability gene has been clearly identified. Promising loci for BP have been identified by candidate gene studies and numerous regions have been implicated by several genome-wide linkage scans (Serretti and Mandelli, 2008). However, such findings have not always been replicated (Cradock and Forty, 2006), and meta-analysis of 18 genome scans on bipolar disorder failed to yield statistically significant linkage results (Segurado et al., 2003). Recently, three groups have performed independent whole genome association studies of bipolar disorder (WTCCC, 2007; Baum et al., 2008; Sklar et al., 2008), but the studies agreed only for a limited number of regions and for the ankyrin 3 (ANK3) (Ferreira et al., 2008; O'Donovan et al., 2009; Smith et al., 2009; Schulze et al., 2009; Scott et al., 2009; Moskvina et al., 2009) gene and alpha 1C subunit of the voltage-dependent calcium channel (CACNA1C) (Ferreira et al., 2008; O'Donovan et al., 2009) genes. This may reflect clinical and genetic heterogeneity of bipolar disorder and lack of a consensus definition for the affected phenotype (Leboyer et al., 1998; Leboyer, 2003). Three different phenotype definitions have commonly been used in genetic studies of BP: a narrow phenotype including BP type I (BPI) and BP type II (BPII, involving milder forms of mania); and a broad phenotype including BPI, BPII and Major Depressive Episode (MDE).

A ‘symptom candidate approach’ has been proposed to disentangle the genetic and clinical heterogeneity of BP, and age at onset (AAO) has proved to be a relevant candidate symptom (Leboyer et al., 1998). Several admixture analyses of AAO demonstrated the existence of three sub-groups, showing a consistent cut-off of 22 years to define early onset forms of BP (Bellivier et al., 2001; Bellivier, 2003; Lin et al., 2006; Hamshere et al., 2008; Manchia et al., 2008). Clinical studies have shown that early-onset BP (EO-BP) is a more severe form of the disorder than later onset forms, and is characterized by more mixed episodes, greater overall psychiatric comorbidity, more lifetime psychotic symptoms and poorer response to prophylactic lithium (Schurhoff et al., 2000; Suominen K et al., 2007). A greater heritability of early-onset than late-onset forms of the disorder has been demonstrated (Weissman et al., 1984; Faraone et al., 2003). Moreover, the pattern of disease inheritance seems to differ between early- and late-onset BP families (Grigoroiu-Serbanescu et al., 2001), suggesting that different genetic mechanisms might be involved.

Through a European Collaborative Study (France, Germany, Ireland, Scotland, Switzerland, England, Slovenia) (Etain et al., 2006), we previously carried out a genome-wide linkage analysis. Two phenotypes were analyzed: a “narrow phenotype” (EO-BPI only) and a “broad phenotype” (including as affected, siblings suffering from either BPI or BPII regardless of AAO, or Major Depressive Episode (MDE) with an early onset). This study suggested linkage for five regions using the broad phenotype (2p21, 2q14.3, 7q36, 10q23 and 20p12); for two regions (5q33 and 16q23) using the narrow phenotype and for one region (3p14) using both narrow and broad phenotypes. These results suggest that the genetic factors involved in the EO-BPI differ from those involved in the other forms of the disease. Genetic heterogeneity according to AAO has already been considered but only in two studies (Faraone et al., 2004; Zandi et al., 2007) and has never been formally tested.

Our aims were to investigate whether phenotypic heterogeneity of the disorder reflects genetic heterogeneity in the eight regions described in our previous study (Etain et al., 2006) using additional markers and an extended sample of families. The MLS statistic was used for linkage analyses. We used two different statistical approaches to test genetic homogeneity: the Predivided Sample Test (PST) (24) and the Maximum Likelihood Binomial (MLB) method (25, 26). This study is the first formal analysis of the relationship between genetic heterogeneity in bipolar disorder and phenotypic heterogeneity, including AAO and severity (BPII versus BPI).

Materials and methods

Subjects

Families were recruited as part of the European Collaborative Study of Early-Onset Bipolar Disorder (see Table I). The ascertainment scheme is detailed elsewhere (Etain et al., 2006). Families were included on the basis of a BP type I proband who suffered one or more thymic episodes before the age of 22 years, and an affected sibling suffering from either BP type I or II (regardless of AAO) or single or recurrent early-onset major depressive episode. In addition to the previously reported sample of 69 families, we include 51 further families (one from Germany, 29 from Spain, four from France, ten from Scotland and seven from Ireland), leading to a total sample size of 120 families. Similar ascertainment criteria were applied to all families. Informed consent was obtained from all participants. The study complied with all ethical guidelines of the institutions involved in each participating country.

Phenotypes analyzed

Age at-onset of BP was defined as the age of the first thymic episode (depressive, manic or hypomanic, determined by reviewing medical case notes and information from semi-structured interviews). Early AAO (EO) was defined as onset before age 22 years. Siblings were considered as affected for the “broad phenotype” if they had BP type I or II or early-onset major depressive episode (MDE). For the “narrow phenotype”, only siblings suffering from EO-BPI were considered to affected, in the same way as for probands. As patients classified at the time of the study as having had a major depressive episode may subsequently suffer from single or recurrent early-onset
major depressive episode, or become BPI or BPII, we chose to exclude siblings with this phenotype from the heterogeneity analysis. As only two siblings suffered from late onset BPII, they were also excluded. Thus, for the heterogeneity analyses, we used only three phenotypes: EO-BPI, LO-BPI and EO-BPII.

Genotyping

Genomic DNA was isolated from peripheral blood leukocytes using a phenol/chloroform method. The initial genome screen included 384 highly polymorphic microsatellite markers (STR for Short Tandem Repeat, see Etain et al., 2006 for details). All families were genotyped for 91 additional STRs in the eight linkage regions. New pedigrees were not genotyped for all genome-scan markers but only for STRs in the eight regions included in this analysis. Marker locations are reported in Kosambi centiMorgans (cM), according to the Marshfield map (http://research.marshfieldclinic.org/). The mean distance between markers was 1.89 (range 1.2 cM to 3 cM). Genotyping was performed at the Centre National de Génotypage (CNG - France).

Statistical methods

Maximum Likelihood Score (MLS) method

Sib-pair linkage analysis assesses the sharing by affected sib-pairs of identical-by-descent (IBD) marker alleles. If the observed IBD distribution differs significantly from that expected under the null hypothesis of independent segregation of the disease and markers, it provides evidence of linkage. Linkage analysis was carried out using the MLS statistic (Risch, 1990), assuming that the IBD proportions, \( z_{AA} \), \( z_{A'A'} \), and discordant pairs (AA and A’A’), are constrained within a triangle defined by \( 2z_{AA} \leq z_i \leq 0.5 \) referred to as the triangle constraints (Suarez et al., 1978; Holmans, 1993). However, if the phenotype of each member of a sib-pair is determined by different genetic models, i.e. corresponding to different genotype relative risks, the triangle constraints may not be valid (Dizier et al., 2000). This can occur when the two sibs differ for a factor, such as a characteristic of the disease, e.g. severe vs. mild form, which modifies the genotype relative risks for the disease. We used a p-value of 0.01 as the cut-off and p-values between 0.0001 and 0.01 were considered to provide indication of linkage.

The Predivided Sample Test (PST)

Let us consider two sub-phenotypes, A and A’. Under the null hypothesis of genetic homogeneity (i.e. the same genotype relative risks for the two sub-phenotypes), the \( Z(z_2, z_1, z_0) \) vectors are expected to be equal for all types of pairs, i.e. concordant pairs (AA and A’A’), and discordant pairs (AA’). The null hypothesis of no linkage can be tested by the PST statistic as proposed by Morton and Steinberg (Morton and Steinberg, 1956): \( -2 \text{Ln} \left( L(Z_{AA}) \cdot L(Z_{A'A'}) \cdot L(Z_{A'A}) / L(Z) \right) \) where \( L(Z_{AA}) \), \( L(Z_{A'A'}) \), \( L(Z_{A'A}) \) and \( L(Z) \) are the likelihoods of the parameter vectors \( Z \), estimated in each sample of pairs (AA, AA’ and A’A’) and the whole sample, respectively. The Z vectors were estimated here without constraints to allow departure from the triangle constraint among discordant sib-pairs in the case of heterogeneity. In the case of three phenotypic categories of sib-pairs, the PST statistic would follow a \( \chi^2 \) with four degrees of freedom (df).

Maximum Likelihood Binomial for ordered categorical traits

The Maximum Likelihood Binomial (MLB) method is a linkage model-free approach which is likelihood-based and can be applied to the whole sibship of affected subjects (Majumder and Pal, 1987; Satsangi et al., 1996; Abel L and Muller-Myhsok, 1998). This method is based on the binomial distribution of the number of affected sibs receiving a given parental allele from heterozygous parents. The probability \( \alpha \) for an affected sib to receive from his/her parent the marker allele transmitted with the disease allele is equal to 0.5 under the null hypothesis of no linkage; \( \alpha \) is greater than 0.5 under the hypothesis of linkage. The test for linkage is performed using a likelihood ratio test statistic, \( \Lambda = 2 \text{Ln} \left[ L(\alpha) / L(\alpha=0.5) \right] \) with the statistic \( \Lambda \) being distributed asymptotically as a mixture distribution of 0.5 \( \chi^2 \) and 0.5 \( \chi^2 \) with one degree of freedom (df) or expressed as a one-sided standard normal deviate denoted \( Z_{MLB} = \sqrt{\Lambda} \). This method has been extended to categorical traits by introducing a latent binary variable \( Y \) \( \equiv \{0:1\} \) which captures the linkage information between the observed categorical phenotype \( Z \) and the marker \( M \). The method requires the assignment of the probability of the latent variable (i.e. being affected or not) according to each observed category of the phenotype. MLBGH (Abel L and Muller-Myhsok, 1998) which incorporates the MLB method into the multipoint approach of Genehunter (Kruglyak et al., 1996) was used for multipoint linkage analyses of polytomous phenotypes. Note that the MLB method for categorical traits can detect linkage accounting for the presence of heterogeneity, and that the PST method can detect both linkage and heterogeneity.

Analysis strategy

Linkage analyses were conducted with the MLS using the triangle constraints, in the whole sample of families and using all available genotypes in the eight regions. For multiple sibships, all independent pairs of affected sibs were considered. Families were ascertained through an EO-BPI proband, and therefore we focused on the detection of genetic heterogeneity between EO-BPI and other forms of the disorder (LO-BPI or EO-BPII).

To limit the number of tests, heterogeneity testing was only applied to markers giving a p-value lower than or equal to 0.05 with the MLS statistic, using either the broad or the narrow phenotypic definition. Two different tests were conducted with the PST, each test
contrasting concordant pairs (both sibs being EO-BPI) to discordant-pairs (first sib being EO-BPI and second sib being either LO-BPI for the first test or EO-BPII for the second test). If one or both tests provided evidence of heterogeneity (p≤0.005), we also conducted the PST contrasting the concordant pairs to the pooled discordant pairs. Because only two categories of sib-pairs were considered, the degree of freedom of the PST was equal to 2. Note that the PST was applied using the MLS without constraints for both concordant and discordant sib-pairs, although departure from the Holmans triangle was expected only among discordant sib-pairs. Thus, for markers showing a significant heterogeneity with the PST, we verified that the p-value ≤0.05 for concordant pairs for BP1-EO using MLS with the triangle constraints.

Using the MLB method, we considered three models of ordered category trait, each model including three categories:

Model 1: EO-BPI > LO-BPI > UNAFFECTED (UA)

Model 2: EO-BPI > EO-BPII> UA

Model 3: EO-BPI > (LO-BPI + EO-BPII)> UA

For the three models, the corresponding probabilities of being affected for the unobserved binary trait given the three ordered categories were fixed to 1, 0.5 and 0.

RESULTS

Description of the sample

A total of 120 nuclear families ascertained through an early onset BPI proband were analyzed. 46.7% of the parents were genotyped. The initial sample of 69 families included 33 independent affected sib-pairs with the narrow phenotype-definition and the additional sample of 51 families included 20 such sib-pairs. Using broad definition the numbers were 76 and 62 sib-pairs respectively. Thus, 53 narrow and 138 broad sib-pairs were used for analysis.

The phenotypic distribution was similar in the initial and the additional samples (p=0.44): the proportions of EO-BPI (p=0.18), LO-BPI (p=0.66) and EO-BPII (p=0.85) siblings did not differ between the two samples (Table I ). All the 138 independent affected sib-pairs were genotyped: 53 siblings were EO-BPI (corresponding to the narrow phenotype), 45 were LO-BPI, 20 were EO-BPII, 18 were EO-MDE and two were LO-BPII. In the whole sample, the mean AAO was 17.2 years for probands and 21.2 years for affected siblings. The sex-ratio (male/female) was 69% for probands and 67.1% for siblings. The distributions of AAO and the sex-ratio between probands and siblings did not differ between the initial and the additional family samples (Table I).

Non parametric linkage analysis in regions of linkage

Genotyping of an additional set of linkage markers led to a mean information content of 90% (versus 0.80 in our initial genome screen) in our eight regions of linkage. Linkage analysis of the initial sample with all markers gave results very similar to those reported previously (results not shown). Multipoint linkage analysis for the broad and narrow phenotypes in the extended sample of families is described in Table 2. For the broad phenotype, linkage was indicated for regions 2q14 (p=0.001), 3p14 (p=0.005) and 20p12 (p=0.007) as in the initial scan; by contrast, no evidence of linkage was found for regions 2p21, 7q36 and 10q23. For the narrow phenotype, linkage was indicated for regions 3p14 (p=0.006) and 16p23 (p=0.004), as in the initial scan. By contrast, there were indications of linkage for the region 2q14 (p=0.004), which had not been identified in the initial genome scan. Unlike previously, no linkage was found for region 5q33 with the narrow phenotype in the whole sample.

Heterogeneity testing

The PST and MLB methods were used to search for genetic heterogeneity for markers in regions of linkage showing a p≤0.05 for narrow and/or broad phenotypes in the whole sample of families. Thirty-six markers fulfilled this criterion. Using the PST, two regions show heterogeneity with a p-value lower than or equal to 0.005 (Table 3). The strongest linkage heterogeneity was detected for the 2q14 region between the phenotypes EO-BPI and LO-BPI (p=0.0001). In contrast, no heterogeneity was found between EO-BPI and EO-BPII in this region. The allele sharing proportion was higher between concordant EO-BPI pairs (0.58) than between BPI pairs discordant for AAO (0.28). There was also some indication of heterogeneity in the region 16p23, between EO-BPI and other forms of the disease (LO-BPI + EO-BPII). The categorical MLB method (Table 4) gave results consistent with those obtained using the PST, in particular confirming the heterogeneity of the 2q14 region. Linkage was detected (p=0.005) for the categorical model EO-BPI > LO-BPI > UA, but not for the model EO-BPI > EO-BPII > UA.

DISCUSSION
Of the eight regions of linkage suggested by our previous genome scan, analysis of the extended sample of families provided indication of linkage to four regions (2q14, 3p14, 16p23 and 20p12). The 3p14 region, detected here, has been reported in several other genome scans (McInnis et al., 1996; Cichon et al., 2001; Kelsoe et al., 2001; Radhakrishna et al., 2001; Ewald et al., 2003; Fallin et al., 2004). However, the 5q33 region, showing linkage in numerous independent reports (Edenberg et al. 1997; Cichon et al., 2001; Kelsoe et al., 2001; McInnis et al., 2003; Herzberg et al., 2006; Jones et al., 2007) did not show linkage in our sample (p=0.04). Our results for the 20p12 region are consistent with several studies (McInnis et al., 2003; Fallin et al., 2004; Jones et al., 2007; Etain et al., 2009). By contrast, the 7q36 region has been reported in only two scans (Jones et al., 2007; Cassidy et al., 2009). As far as we know, the 16p23 region has never previously been reported in bipolar genome scan.

Indication of linkage was shown here for the 2q14 region for both the narrow and the broad phenotypes in the extended sample of families although no evidence for linkage was found for the narrow phenotype in the initial sample of families. The initial sample included only 29 concordant EO-BPI sib-pairs, whereas 53 were included in this study. The region has been identified in three previous genome scans (Dick et al. 2003; Fallin et al., 2004; Pato et al., 2004) and by the meta-analysis reported by Segurado et al. (Segurado et al., 2003); note that none of these studies considered AAO in their analyses. One of the four genome-wide association studies conducted for bipolar disorder (WTCCC, 2007; Baum et al., 2008, Ferreira et al., 2008, Sklar et al., 2008), the Wellcome Trust Case control consortium, reported moderate evidence for association of bipolar disorder in the 2q14 region (p=10^-6). This region however gave no or only weak signals for association in the three other studies. Similarly to previous linkage studies, AAO was not taken into account in these genome-wide association studies. Recently, Le Niculescu et al. proposed a convergent genetic approach, integrating the results from GWA studies, functional genomics and animal models, and suggested the Dpp10 gene as a relevant candidate gene in this region (Le-Niculescu et al., 2009). Note that, although not yet tested, the 2q14 region also contains other candidate genes, particularly CNTNAP5, GPR7 and HS6ST1.

Only two previous genome-wide linkage studies of BP contained AAO (Faraone et al., 2004; Zandi et al., 2007). Faraone et al. carried out linkage analysis using AAO as a quantitative trait in BPI families and concluded that genes localized in 12p, 14q and 15q regions influenced AAO of mania and were distinct from those influencing the liability to develop BP. Zandi et al. (Zandi et al., 2007) reported the 3q28 region in a genome-wide linkage analysis of BP adjusted for AAO. Thus, there are discrepancies between the findings of these two earlier studies that took AAO into account and our study. There are several methodological issues that may explain these discrepancies. There are differences in the statistical methods used in the three studies: the variance-component method for Faraone’s study, the conditional logistic linkage approach in Zandi’s study, and the MLS, PST and MLB statistics used here. In addition, in Faraone’s study, AAO was defined as the age at the first manic episode and was analyzed as a quantitative trait, whereas Zandi and colleagues, like us, defined AAO as the age at the first thymic episode, whether manic, hypomanic or depressive, and analyzed it as a binary trait (using a threshold of 21 years old). The modes of ascertainment used by these studies also differ: our families were ascertained through an EO-BPI proband and an affected sibling suffering either from BPI or BPII (regardless of AAO) or EO-MDE, whereas the other studies included families with two BPI patients (Faraone et al., 2004) or with a BPI proband and at least two first-degree relatives affected by BP (Zandi et al., 2007).

Heterogeneity testing allowed the identification of genetic heterogeneity between EO-BPI and LO-BPI in the 2q14 region, suggesting linkage heterogeneity according to the AAO. The excess sharing of parental alleles between pairs concordant for EO-BPI but not between discordant sib-pairs (one sib with EO-BPI, the other LO), indicated linkage of this region to only the early form of the disorder. The failure to detect heterogeneity between EO-BPI and EO-BPII could be a consequence of a lack of power due to the small number of discordant pairs, or of a dependence of the two forms of the disease (EO-BPI and EO-BPII) on the same genetic factor in 2q14 region. The MLB results were consistent with heterogeneity in the 2q14 region: this approach supports linkage to the 2q14 region allowing for heterogeneity under the model EO-BPI > LO-BPI > UA. The significance level was lower than with the PST, the power of the two methods being dependent on the underlying model. In our sample, the PST method detected linkage in the 2q14 region with greater significance than found with classical linkage analysis (p=0.0001 versus p=0.001, without correction for multiple testing). We used a relatively stringent threshold (p ≤ 0.005) to select regions because of the increase of type one error due to multiple testing. We conducted tests for 36 markers, for two independent models (EO-BPI versus LO-BPI and EOBPI versus EO-BPII), and with both PST and MLB methods. A total of 144 tests were conducted, but not all the tests were independent. Although Bonferroni’s correction is known to be over-conservative for non-independent tests, the results of the PST analysis in the 2q14 region using this correction remained significant (p=0.01). By contrast, the result for the 16p23 region was not significant after Bonferroni’s correction.

Our results clearly illustrated the value of such heterogeneity testing for detecting linkage, and particularly its greater power to detect linkage accounting for possible genetic heterogeneity when it exists. Moreover, even without large samples, this approach allowed the detection of significant genetic heterogeneity in the 2q14 region according to AAO of BPI.

These various results indicate that a genetic factor located in the 2q14 region is either specifically involved in the early onset BP, or is involved in only the AAO acting like a modifier gene (a gene which modifies the effect of another gene). As BP is a multi-factorial
disease, it is difficult to prove that the gene in 2q14 influences the AAO and thereby modifies the effect of another gene; numerous genes are involved in BP and they are likely to interact. We could have conducted heterogeneity tests, controlling for the other linked regions (by stratifying between families linked or not linked to another region), but our sample size is not large enough, the resulting groups would be too small for satisfactory statistical analysis. For the other linkage regions detected in this study, no heterogeneity was detected according AAO. This suggests that there are also some genetic factor(s) shared by early and late onset BP. The existence of such shared genetic component(s) is supported by the presence of late onset BP individuals among sibships of early onset BP probands.

A major issue in the identification of susceptibility genes for BP disorder is the choice of the heritable phenotype to study. BPI, BPII and MDE are defined as distinct entities in DSM-IV, which allows a high inter-rater concordance but which was not constructed to distinguish between different clinical entities depending on distinct genetic factors. Most genome-wise linkage scans have analyzed broad, intermediate and narrow phenotypes using a gradient from MDE to BPI through BPII (Garner et al., 2001; McNinns et al., 2003; Fallin et al., 2004; Schumacher et al., 2005; Zandi et al., 2007; Vazza et al., 2007; Nwulila et al., 2007; Venken et al., 2007). This phenotypic classification may not be the most appropriate for defining phenotypes for the linkage regions. Indeed, our results for the 2q14 region show that stratification according to AAO may be more relevant than DSM-IV classifications of mood disorders. Further genome-wide association studies including candidate genes in this region will help shed light on the various etiological pathways involved in BP according to the AAO.

Acknowledgements:

Grant sponsor: INSERM; Grant sponsor: Assistance Publique des Hôpitaux de Paris; Grant sponsor: Agence Nationale pour la Recherche (ANR-Project Manage-BP); Grant sponsor: National Alliance for Research on Schizophrenia and Depression (NARSD); Grant sponsor: Fondation pour la Recherche sur le Cerveau (FRC); Grant sponsor: RTRS Santé Mentale (FondaMental); Grant sponsor: National Genomic Network (NGFN) of the German Ministry of Education and Research; Grant sponsor: Deutsche Forschungsgemeinschaft (SFB 400 Subprojects D1 and D3, Graduiertenkolleg GRK 246, FOR 423 Subproject D1); Grant sponsor: Alfried Krupp von Bohlen und Halbach-Stiftung; Grant sponsor: Interuniversity Attraction Poles program P5/19 of the Belgian Federal Science Policy Office; Grant sponsor: German Research Society (Grant Numbers: AL 230-1/2-5/1, SFB 400); Grant sponsor: Aware; Grant sponsor: Health Research Board (Grant Number: H01069 HRB RP153/2000); Grant sponsor: Friends of St. Patrick’s Hospital; Grant sponsor: Swiss National Foundation (Grant Numbers: 32-40677.94, 32-47315.96, 32-061974.00, 32-66793.01, 32-102168.03).

References:

- Abel L, Alcais A, Mallet A. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry. 2008; 13 (2): 197 - 207
- Cassidy F, Zhao C, Badger J, Claffey E, Dobrin S, Roche S. Genome-wide scan of bipolar disorder and investigation of population stratification effects on linkage: support for susceptibility loci at 4q11, 7q16, 9p12, 12q24, 14q24, and 16p13. Am J Med Genet B Neuropsychiatr Genet. 2007; Sep 144B: (6) 791 - 801
- Dizier MH, Quevresseille H, Prum B, Selinger-Leneman H, Clergon-Darpoux F. The triangle test statistic (TTS): a test of genetic homogeneity using departure from the

34

expected allele frequency for linkage at 314. Mol Psychiatry. 2006; Jul 11: (7) 685 - 694
- Farone SV, Glatt SJ, Su J, Tsuang MT. Three potential susceptibility loci shown by a genome-wide scan for regions influencing the age at onset of mania. Am J Psychiatry 2004; Apr 161: (4) 625 - 630
- Farone SV, Glatt SJ, Tsuang MT. The genetics of pediatric-onset bipolar disorder. Biol Psychiatry. 2003; Jun 1 53: (11) 970 - 977
- Ferreira MA, O'Donnovan MC, Meng YA, Jones BR, Ruderfer DM, Jones L. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet. 2008; Sep 40: (9) 1056 - 1058

Am J Med Genet B Neuropsychiatr Genet. Author manuscript
Genetic heterogeneity of bipolar disorder

- Venken T, Del-Favero J. Chasing genes for mood disorders and schizophrenia in genetically isolated populations. Hum Mutat. 2007; Dec 28: (12) 1156 - 1170
Table 1
Description of the sample

<table>
<thead>
<tr>
<th></th>
<th>INITIAL SAMPLE</th>
<th>ADDITIONAL SAMPLE</th>
<th>INITIAL vs. ADDITIONAL</th>
<th>EXTENDED SAMPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Proband</td>
<td>Sibs</td>
<td>Proband</td>
<td>Sibs</td>
</tr>
<tr>
<td>Number of affected</td>
<td>69</td>
<td>76</td>
<td>51</td>
<td>62</td>
</tr>
<tr>
<td>Mean age at onset (Std dev)</td>
<td>17.41 (2.41)</td>
<td>21.66 (6.84)</td>
<td>16.94 (2.61)</td>
<td>20.65 (7.20)</td>
</tr>
<tr>
<td>Sex ratio (male/female)</td>
<td>72.5% (29/40)</td>
<td>62.5% (30/48)</td>
<td>64.5% (20/31)</td>
<td>73.0% (27/37)</td>
</tr>
<tr>
<td>Early BPI</td>
<td>69 (100%)</td>
<td>33 (43.4%)</td>
<td>51 (100%)</td>
<td>20 (32.3%)</td>
</tr>
<tr>
<td>Later BPI</td>
<td>-</td>
<td>26 (34.2%)</td>
<td>-</td>
<td>19 (30.6%)</td>
</tr>
<tr>
<td>Early BPII</td>
<td>-</td>
<td>11 (14.5%)</td>
<td>-</td>
<td>9 (14.5%)</td>
</tr>
<tr>
<td>Later BPII</td>
<td>-</td>
<td>0</td>
<td>-</td>
<td>2 (3.2%)</td>
</tr>
<tr>
<td>Early MDE</td>
<td>-</td>
<td>6 (7.9%)</td>
<td>-</td>
<td>12 (19.4%)</td>
</tr>
</tbody>
</table>

Table 2
Results of the MLS using the triangle constraints with the eight linkage regions in the extended family sample

<table>
<thead>
<tr>
<th>Region of linkage</th>
<th>Phenotype</th>
<th>Genetic location Distance from p-ter (cM)</th>
<th>MLS max</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>2p21</td>
<td>Broad</td>
<td>65.94</td>
<td>0.64</td>
<td>Ns</td>
</tr>
<tr>
<td></td>
<td>Narrow</td>
<td>65.94</td>
<td>0.70</td>
<td>Ns</td>
</tr>
<tr>
<td>2q14</td>
<td>Broad</td>
<td>131.51</td>
<td>2.26</td>
<td>p = 0.001</td>
</tr>
<tr>
<td></td>
<td>Narrow</td>
<td>128.41</td>
<td>1.75</td>
<td>p = 0.004</td>
</tr>
<tr>
<td>3p14</td>
<td>Broad</td>
<td>85.97</td>
<td>1.66</td>
<td>p = 0.005</td>
</tr>
<tr>
<td></td>
<td>Narrow</td>
<td>85.97</td>
<td>1.60</td>
<td>p = 0.006</td>
</tr>
<tr>
<td>5q33</td>
<td>Broad</td>
<td>153.17</td>
<td>0.32</td>
<td>Ns</td>
</tr>
<tr>
<td></td>
<td>Narrow</td>
<td>150.34</td>
<td>0.86</td>
<td>p = 0.04</td>
</tr>
<tr>
<td>7q36</td>
<td>Broad</td>
<td>165.18</td>
<td>1.17</td>
<td>p = 0.02</td>
</tr>
<tr>
<td></td>
<td>Narrow</td>
<td>162.33</td>
<td>0.54</td>
<td>Ns</td>
</tr>
<tr>
<td>10q23</td>
<td>Broad</td>
<td>116.34</td>
<td>0.43</td>
<td>Ns</td>
</tr>
<tr>
<td></td>
<td>Narrow</td>
<td>116.34</td>
<td>0.11</td>
<td>Ns</td>
</tr>
<tr>
<td>16p23</td>
<td>Broad</td>
<td>100.39</td>
<td>0.04</td>
<td>Ns</td>
</tr>
<tr>
<td></td>
<td>Narrow</td>
<td>100.39</td>
<td>1.71</td>
<td>p = 0.004</td>
</tr>
<tr>
<td>20p12</td>
<td>Broad</td>
<td>32.30</td>
<td>1.50</td>
<td>p = 0.007</td>
</tr>
<tr>
<td></td>
<td>Narrow</td>
<td>37.65</td>
<td>0.91</td>
<td>p = 0.03</td>
</tr>
</tbody>
</table>

* Marker locations (distance from p-ter) were extracted from the Marshfield database (http://research.marshfieldclinic.org).
Table 3
Results of the PST: regions showing a $p \leq 0.005$ for at least one model

<table>
<thead>
<tr>
<th>Region</th>
<th>Distance from p-ter</th>
<th>Physical location Mb</th>
<th>Phenotype tested</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>2q14</td>
<td>118</td>
<td>106.5</td>
<td>EO-BPI vs. LO-BPI</td>
<td>0.0001</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>EO-BPI vs. EO-BPII</td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>EO-BPI vs. LO-BPI or EO-BPII</td>
<td>0.001</td>
</tr>
<tr>
<td>16p23</td>
<td>97</td>
<td>77.5</td>
<td>EO-BPI vs. LO-BPI</td>
<td>0.03</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>EO-BPI vs. EO-BPII</td>
<td>0.01</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>EO-BPI vs. LO-BPI or EO-BPII</td>
<td>0.005</td>
</tr>
</tbody>
</table>

Table 4
Results of the categorical MLB method: regions showing $p \leq 0.005$ for at least one model

<table>
<thead>
<tr>
<th>Region</th>
<th>Distance from p-ter</th>
<th>Phenotype tested</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>2q14</td>
<td>127 cM</td>
<td>EO-BPI &gt; LO-BPI &gt; UA</td>
<td>0.005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EO-BPI &gt; EO-BPII &gt; UA</td>
<td>0.01</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EO-BPI &gt; LO-BPI or EO-BPII &gt; UA</td>
<td>0.005</td>
</tr>
</tbody>
</table>